Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Partnership    entities : Abbvie inc.    save search

AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
Published: 2024-02-28 (Crawled : 06:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.6% H: 0.02% C: -1.03%

partnership abbvie antibody treatment
AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact
Published: 2022-12-15 (Crawled : 17:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.59% H: 0.44% C: -0.48%

partnership antibody
AMCP Foundation Interns Delve into Oncology, Evidence Gaps, Medication Adherence in Partnership with AbbVie Inc. and Pfizer Inc.
Published: 2022-11-17 (Crawled : 17:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.59% H: 1.39% C: 0.79%

partnership
Off to Stratospheric 2022 Start, AbbVie Announces New Protein Degradation Partnership
Published: 2022-04-28 (Crawled : 15:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.6% H: 0.0% C: 0.0%

partnership
AbbVie Pulls Plug on Parkinson’s Partnership With BioArctic
Published: 2022-04-20 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
| | O: -2.48% H: 0.0% C: 0.0%

partnership
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
Published: 2020-12-02 (Crawled : 15:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.04% H: 1.33% C: 0.95%

therapy partnership drug
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
Published: 2020-12-02 (Crawled : 15:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.04% H: 1.33% C: 0.95%

therapy partnership drug
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services

INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.